MX2020006005A - Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca. - Google Patents

Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.

Info

Publication number
MX2020006005A
MX2020006005A MX2020006005A MX2020006005A MX2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A
Authority
MX
Mexico
Prior art keywords
heart failure
block copolymers
amphiphilic block
treating
methods
Prior art date
Application number
MX2020006005A
Other languages
English (en)
Inventor
Afsaneh Lavasanifar
Anthony Ernest Bolton
Original Assignee
Cardiol Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiol Therapeutics Inc filed Critical Cardiol Therapeutics Inc
Publication of MX2020006005A publication Critical patent/MX2020006005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Copolímeros bloque anfifílicos formadores de micelas que se usan para dirigirse a células cardíacas (por ejemplo, células fibróticas) de un sujeto que padece insuficiencia cardíaca, micelas que contienen los copolímeros bloque anfifílicos formadores de micelas junto con un agente cardioactivo y composiciones y métodos relacionados para tratar o prevenir la insuficiencia cardíaca, por ejemplo insuficiencia cardíaca con fracción de eyección preservada (HFpEF) también conocida como insuficiencia cardíaca diastólica.
MX2020006005A 2017-12-12 2018-12-10 Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca. MX2020006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597740P 2017-12-12 2017-12-12
PCT/CA2018/051573 WO2019113685A1 (en) 2017-12-12 2018-12-10 Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure

Publications (1)

Publication Number Publication Date
MX2020006005A true MX2020006005A (es) 2020-08-17

Family

ID=66818773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006005A MX2020006005A (es) 2017-12-12 2018-12-10 Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.

Country Status (7)

Country Link
US (1) US20210085801A1 (es)
EP (1) EP3723731A4 (es)
AU (1) AU2018384096B2 (es)
BR (1) BR112020006191A2 (es)
CA (1) CA3076248A1 (es)
MX (1) MX2020006005A (es)
WO (1) WO2019113685A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553635A (ja) * 2019-10-25 2022-12-26 カーディオル セラピューティクス インコーポレイテッド 心臓病態の治療に使用するためのカンナビジオール組成物
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
CA3178819A1 (en) * 2020-05-26 2021-12-02 Chuanhai Cao Cannabinoid compositions and dosage forms for intranasal or inhalational delivery
CN114262442B (zh) * 2021-12-24 2023-05-02 厦门金达威生物科技有限公司 一种两亲聚合物和脂溶性营养素纳米颗粒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
JP4723244B2 (ja) * 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
US20080038353A1 (en) * 2004-06-02 2008-02-14 The Governors Of The University Of Alberta Polymer Based Nano-Carriers For The Solubilization And Delivery Of Hydrophobic Drugs
WO2007106997A1 (en) * 2006-03-21 2007-09-27 The Governors Of The University Of Alberta Novel poly(ethylene oxide)-block-poly(ester) block copolymers
EP2382966A1 (en) * 2010-03-12 2011-11-02 DSM IP Assets B.V. Micelle compositions and process for the preparation thereof
AU2014244053B2 (en) * 2013-03-13 2018-08-30 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist

Also Published As

Publication number Publication date
AU2018384096A1 (en) 2020-03-26
EP3723731A4 (en) 2021-10-20
BR112020006191A2 (pt) 2020-10-06
CA3076248A1 (en) 2019-06-20
US20210085801A1 (en) 2021-03-25
EP3723731A1 (en) 2020-10-21
WO2019113685A1 (en) 2019-06-20
AU2018384096B2 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MX2020006005A (es) Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
EP4339287A3 (en) Modified cells and methods of therapy
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
WO2017093804A3 (en) Materials and methods for treatment of alpha-1 antitrypsin deficiency
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
WO2015168149A3 (en) Sensorineural hair cell differentiation
WO2016037138A8 (en) Globin gene therapy for treating hemoglobinopathies
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
WO2014015274A8 (en) Methods for tissue passivation
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
WO2018220489A3 (en) METHODS OF OBTAINING CELLS FROM HUMAN OMBILICAL POST-PARTUM CORDON ARTERIAL TISSUE
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
WO2016130581A3 (en) Combination cancer therapy
WO2013170086A3 (en) Formulations for the delivery of active ingredients
WO2016205397A3 (en) Target-specific delivery of therapeutic agents
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
MX2022015488A (es) Tratamiento para la disfuncion auricular.
WO2015149006A3 (en) Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin